- This RMAT designation is based on data from 3 clinical studies demonstrating the potential benefit of AAV-GAD as a one-time treatment for Parkinson’s disease - RMAT designation includes the benefits of the Fast Track and Breakthrough Therapy designations, allows frequent regulatory interactions with the FDA, and potential routes to accelerated approval and Priority Review LONDON and NEW YORK, May 09, 2025 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical-stage gen ...

enGene Holdings (ENGN) 2025 Conference May 05, 2025 02:00 PM ET Speaker0 For our next presentation, it's from NGIN, and we have the pleasure of having Ron Cooper, the CEO, here to present for us. So take it away, Ron. Thank you. Speaker1 Well, good afternoon, everybody. It's a real pleasure to be here. You know, first of all, thanks to the conference organizers. It's great to be back in back in Canada. NGEN is a company form formed in Canada. Our headquarters is in Montreal. Our labs are there, and we have ...